Breaking News

Novartis Acquires CoStim

By Gil Roth | February 18, 2014

Expands cancer immunotherapy, adds immune-modulating targets and technology

Novartis has acquired CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer. The move is intended to broaden Novartis' cancer immunotherapy research program. Novartis will add late discovery stage immunotherapy programs directed to several targets, including PD-1. Financial terms are not disclosed.

"Therapy for many types of cancers are expected to increasingly rely upon rational combinations of agents," said Dr. Mark Fishman, President of the Novartis Institutes for BioMedical Research. "Immunotherapy agents provide additional arrows in our quiver for such combinations. They complement our extensive portfolio of drugs that hit genetically-defined cancer-causing pathways, and also may be relevant to expansion of chimeric antigen receptor (CAR) therapies."

Related Contract Manufacturing:

  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus